Anshul Maheshwari Sells 5,304 Shares of SI-BONE, Inc. (NASDAQ:SIBN) Stock

SI-BONE, Inc. (NASDAQ:SIBN) CFO Anshul Maheshwari sold 5,304 shares of the company’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $13.91, for a total value of $73,778.64. Following the sale, the chief financial officer now owns 189,319 shares of the company’s stock, valued at approximately $2,633,427.29. This trade represents a 2.73 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Anshul Maheshwari also recently made the following trade(s):

• On Monday, November 18th, Anshul Maheshwari sold 2,439 shares of SI-BONE stock. The shares were sold at an average price of $12.68, for a total value of $30,926.52.

SI-BONE Stock Performance

SIBN opened at $14.40 on Thursday. The company has a 50 day simple moving average of $13.66 and a two-hundred day simple moving average of $14.17. The company has a debt-to-equity ratio of 0.22, a current ratio of 8.25 and a quick ratio of 7.22. The firm has a market cap of $603.91 million, a P/E ratio of -15.65 and a beta of 1.16. SI-BONE, Inc. has a 1-year low of $11.70 and a 1-year high of $21.64.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of SIBN. Champlain Investment Partners LLC raised its holdings in SI-BONE by 14.7% during the third quarter. Champlain Investment Partners LLC now owns 2,800,073 shares of the company’s stock valued at $39,145,000 after acquiring an additional 358,821 shares during the period. American Century Companies Inc. raised its stake in SI-BONE by 22.8% during the 2nd quarter. American Century Companies Inc. now owns 1,986,476 shares of the company’s stock valued at $25,685,000 after purchasing an additional 368,637 shares during the period. Bellevue Group AG lifted its holdings in SI-BONE by 4.1% in the 3rd quarter. Bellevue Group AG now owns 1,444,109 shares of the company’s stock worth $20,189,000 after purchasing an additional 56,500 shares in the last quarter. Paradigm Capital Management Inc. NY boosted its stake in SI-BONE by 24.7% in the 2nd quarter. Paradigm Capital Management Inc. NY now owns 1,349,400 shares of the company’s stock worth $17,448,000 after purchasing an additional 267,100 shares during the period. Finally, State Street Corp grew its holdings in SI-BONE by 5.1% during the 3rd quarter. State Street Corp now owns 1,081,871 shares of the company’s stock valued at $15,125,000 after buying an additional 52,972 shares in the last quarter. Institutional investors own 98.11% of the company’s stock.

Wall Street Analyst Weigh In

SIBN has been the topic of a number of research reports. Needham & Company LLC reissued a “buy” rating and issued a $19.00 price objective on shares of SI-BONE in a report on Wednesday, November 20th. Truist Financial boosted their price objective on shares of SI-BONE from $16.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, SI-BONE presently has an average rating of “Buy” and a consensus price target of $23.00.

SI-BONE Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.